海南粗榧新碱衍生物HH07A经大鼠肝微粒体的代谢转化研究

用大鼠肝微粒体体外代谢法对HH07A进行了代谢转化研究。用HPLC结合二极管阵列检测器对体外代谢体系进行了分析,判断在体外代谢体系中HH07A有二个代谢产物,并用减压柱色谱、薄层色谱及高效液相色谱法分离制备了其中一个代谢物的纯品,经核磁共振、质谱、红外、紫外光谱确定了结构。     

诺乙龙体内代谢物的GC-MS分析鉴定

GC-MS联用分析诺乙龙阳性尿,检出了诺乙龙经人体吸收代谢以后产生的九个代谢产物。除Met-2和Met-7在服药后84h的尿样中仍能被检出以外,诺乙龙原型及其它代谢物的体内存留时间较短,可检测时间不超过35h。通过解析质谱,鉴定了七个代谢物的分子结构,发现A环双键还原和D环羟基化是诺乙龙的两种体内代谢途径.用大孔树脂吸附提取、酶解、衍生化等处理尿样,方法回收率达80%,诺乙龙的检测下限为10ng/ml(10 ppb).     

脱氢氯甲睾酮人体内代谢研究

本文叙述了用GC-MS联用技术研究脱氢氯甲睾酮人体内代谢的方法。尿样中的甾体化合物经大孔树脂吸附提取后,酶解。浓缩并衍生化,进行GC-MS分析。在服药后8～30h的尿样中,检出了脱氢氯甲睾酮原型,并发现了七个代谢产物。分析色谱和质谱数据,得到了这些代谢物的结构及其浓度变化趋势,推测了脱氢氯甲睾酮可能的体内代谢模式,确定了筛检尿中脱氢氯甲睾酮的特定代谢物和特征检测离子,比较了不同的样品处理方法对分析结果的影响。     

尼莫地平在人肝微粒体内的代谢

:采用人肝微粒体在体外研究尼莫地平 (Nim)在人体内的代谢物及代谢途径 . Nim在人肝微粒体内被迅速代谢成 3个代谢物 ,分别是 Nim二氢吡啶环脱氢代谢物 M1,二氢吡啶环侧链脱甲基代谢物M2 ,二氢吡啶环脱氢及其侧链脱甲基代谢物 M3.Nim在人肝微粒体中的最初的两步代谢反应是其二氢吡啶环脱氢氧化及其侧链脱甲基反应 ,两者的代谢产物可以被进一步代谢为代谢物 M3.CYP3A的特异性抑制剂醋竹桃霉素和酮康唑可以抑制Nim的二氢吡啶环脱氢氧化及其侧链脱甲基反应 ,使 Nim的代谢速率明显下降 ,结果提示 CYP3A参与了 Nim在人肝微粒体内的代谢     

人肝CYP3A参与了山冈橐吾碱的代谢及其肝毒性代谢物的形成(英文)

目的　在体外研究山冈橐吾碱在人肝微粒体内的代谢及参与其代谢的主要的CYP4 5 0酶 ,探讨其代谢致毒机理。方法　采用人肝微粒体研究山冈橐吾碱的主要代谢方式和代谢物。在体外运用CYP4 5 0酶的选择性抑制剂和cDNA表达的人肝CYP4 5 0酶 ,探讨其对山冈橐吾碱的代谢及肝毒性的吡咯代谢物形成的影响及参与山冈橐吾碱代谢的主要的CYP4 5 0酶。结果　山冈橐吾碱在人肝微粒体内的主要代谢物为肝毒性的吡咯代谢物 :去氢倒千里光裂碱 ,7 谷胱甘肽基 去氢倒千里光裂碱 ,7,9 二谷胱甘肽基去氢倒千里光裂碱和山冈囊吾酸。CYP4 5 0特异性抑制剂α 萘黄酮 (抑制CYP1A2 )、黄胺苯吡唑 (抑制CYP2C)、奎尼丁 (抑制CYP2D6 )和二乙基二硫代氨基甲酸钠 (抑制CYP2E1)对山冈橐吾碱的代谢无明显的影响。但CYP3A的特异性抑制剂酮康唑和三乙酰竹桃霉素可以显著地抑制山冈橐吾碱的代谢及其吡咯代谢物和结合型吡咯物的形成。此外 ,在cDNA表达的人肝CYP3A4的温孵液中 ,山冈橐吾碱被代谢成相应的吡咯代谢物 ,而山冈橐吾碱在cDNA表达的人肝CYP1A2、CYP2C9、CYP2D6和CYP2E1温孵液中无代谢。结论　山冈橐吾碱在人肝微粒体内的主要代谢方式是形成肝毒性吡咯代谢物 ,CYP3A作为主要的CYP4 5 0酶参与了山冈橐吾碱的代谢及其肝毒性吡咯代谢?     

海南粗榧新碱衍生物 HH07A 对 DNA 聚合酶 I 活性的影响

用体外DNA聚合酶I作用下DNA合成的方法,研究HH07A的作用机制。结果表明,HH07A对DNA聚合酶I催化下的DNA合成有明显抑制作用,且在一定浓度范围内存在浓度依赖性。将药物与DNA模板及DNA聚合酶I分别预保温后,发现DNA模板活性无明显改变,而酶的活性则受到显著抑制。提示HH07A对DNA聚合酶I催化下DNA合成的抑制是通过HH07A与DNA聚合酶I直接作用而实现的。     

环孢素A代谢物的研究概况

环孢素A是具有免疫抑制活性的环状多肽,在临床上被用于多种器官或骨髓移植患者的抗排斥反应,并可治疗自身免疫性疾病。环孢素A主要在胃肠道由肝药酶CYP3A家族代谢,得到超过30种代谢物,经胆汁排泄。初级代谢物AM1、AM9、AM4N等具有较显著的免疫抑制活性和肝肾毒性。免疫法可同时检测环孢素A及其代谢物的总浓度,而高效液相色谱法则可分别检测二者的浓度。患者的生理或病理状态也影响环孢素A及其代谢物在体内的分布。     

抗焦虑新药AF-5及其代谢物在人肝微粒体体外温孵体系中代谢研究

目的研究一类抗焦虑新药AF-5及其代谢物(I,II)在人肝微粒体体外温孵体系中代谢情况.方法自制人肝微粒体,用Lowry法测定酶活性为8.79mg·mL^-1.以此配制人肝微粒体体外温孵体系,加入药物,温孵后,提取分离,GC-MS测定.结果鉴定了AF-5在人肝微粒体体外温孵体系中的两个主要代谢物,并阐明了其体外代谢途径为AF-5的4位首先氧化为羟基,然后氧化成羰基.结论AF-5在体外人肝微粒体温孵体系中,100min后完全代谢成羟基代谢物I及羰基代谢物II,以羟基代谢物为主要代谢产物.AF-5代谢物I在人肝微粒体温孵体系中,可转化为代谢物II,而代谢物II在人肝中则不再代谢.     

左旋一叶碱的代谢转化

目的研究一叶碱［securinine,(-)SE］在大鼠体内外的代谢转化。方法采用大鼠肝微粒体体外温孵法对(-)SE的代谢转化进行了研究,优化了代谢体系,建立了反相HPLC法同时分离检测(-)SE及其体外代谢产物的分析方法。用液液萃取,制备TLC及半制备HPLC分离纯化了4个代谢产物并进行了光谱鉴定。在此基础上,建立了生物体液中(-)SE及其代谢物的反相HPLC分析方法,并用该法检测了ip给药后大鼠的胆汁、尿样及其经β-葡糖醛酸苷酶水解后的样品。结果代谢物分别鉴定为6-位羟基,6-位羰基及5-位α及β羟基取代的(-)SE,还证实了体内6-位羟基代谢物进一步形成了二相结合型产物。结论基本阐明(-)SE在大鼠体内外代谢转化的途径。     

左旋一叶萩碱的代谢转化

目的　研究一叶碱 [securinine ,( - )SE]在大鼠体内外的代谢转化。方法　采用大鼠肝微粒体体外温孵法对 ( - )SE的代谢转化进行了研究 ,优化了代谢体系 ,建立了反相HPLC法同时分离检测 ( - )SE及其体外代谢产物的分析方法。用液液萃取 ,制备TLC及半制备HPLC分离纯化了 4个代谢产物并进行了光谱鉴定。在此基础上 ,建立了生物体液中 ( - )SE及其代谢物的反相HPLC分析方法 ,并用该法检测了ip给药后大鼠的胆汁、尿样及其经 β 葡糖醛酸苷酶水解后的样品。结果　代谢物分别鉴定为 6 位羟基 ,6 位羰基及 5 位α及 β羟基取代的 ( - )SE ,还证实了体内 6 位羟基代谢物进一步形成了二相结合型产物。结论　基本阐明 ( - )SE在大鼠体内外代谢转化的途径     

6-甲氧基正丁苯酞的体内代谢转化研究

大鼠用6-甲氧基正丁苯酞(MBP)灌胃,收集0～24h尿液,经酶水解、提取浓缩、衍生化处理后用GC/MS分析。在大鼠0～24h尿液中,6-甲氧基正丁苯酞原药含量很低,主要以代谢物形式存在,依次为C-6脱甲基产物、C₃-C_α环氧化物、γ-羟化物、β-羟化物以及两个次级代谢产物。6-甲氧基正丁苯酞体内代谢结果与其在肝微粒体中代谢结果基本一致。     

海南粗榧新碱衍生物HH07A对肿瘤细胞内DNA拓扑异构酶Ⅱ和蛋白激酶C活性的影响

HH07A 5.5 μmol·L^-1作用L1210细胞24 h后, 可使细胞的DNA拓扑异构酶Ⅱ活性下降; 在无细胞系统, HH07A 0.55 mmol·L^-1也能直接促进DNA拓扑异构酶Ⅱ引起的DNA链断裂. 经HH07A (L1210细胞5.5 μmol·L^-1, HL-60细胞8.25 μmol·L^-1)作用24 h后, L1210及HL-60细胞的胞浆蛋白激酶C(PKC)活性升高, 胞膜PKC活性下降, 而全细胞PKC活性变化不大. 在无细胞系统中, HH07A 1.1 mmol·L^-1能明显抑制PKC的活性.     

海南粗榧新碱衍生物HH07A的抗肿瘤作用

用细胞生长曲线测定法及软琼脂集落形成分析法研究了HH07A对几种肿瘤及正常细胞生长的影响。结果表明,1.5ug·ml^-1及3μg·ml^-1HH07A能分别明显抑制L1210和HL-60细胞的生长。3种肿瘤细胞对HH07A的敏感性依次为L1210>KB>HL-60,而正常小鼠粒系祖细胞GM-CPC对药物的敏感性则低于前三者,且HH07A3.5μg·ml^-1对HL-60细胞无分化诱导作用。HH07A对腹水型L1210白血病小鼠、S180小鼠均有较明显的治疗作用,使L1210荷瘤小鼠、S180荷瘤小鼠存活时间延长。也能抑制S180实体瘤的生长。     

海南粗榧新碱衍生物HH07A对体外L1210细胞的杀伤作用

体外培养的小鼠L1210细胞被HH07A2μg·ml^-1作用24h后,与对照组细胞相比,其细胞数不再增长,有丝分裂数及集落形成率下降,细胞形态及细胞周期动力学均发生一定的变化。且HH07A大剂量短期作用抑制Ll210细胞集落形成的效率高于低剂量持续作用。     

Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes

A gas chromatography-mass spectrometry (GC-MS) procedure for the detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine is presented. The metabolites were first identified in rat liver microsome preparations by GC-MS after isolation and derivatization. Using these GC-MS data, a GC-MS screening was developed for urine as part of the authors' modified systematic toxicologic analysis procedure. After acid hydrolysis of a 2.5-mL aliquot of urine, a further aliquot was added. The mixture was then liquid-liquid extracted at pH 8-9, acetylated, and GC separated. Using mass chromatography with the ions m/z 58, 100, 120, 182, 195, 235, 261, 276, 284. and 293, the presence of new antidepressants, neuroleptics, hypnotics, and their metabolites could be indicated. Positive peaks could be identified by library search using the reference mass spectra recorded during the microsome studies. The intake of therapeutic doses of the following drugs could be monitored in urine: dosulepin, mirtazapine, moclobemide, nefazodone, trazodone, venlafaxine, and zolpidem. Olanzapine and zotepine were detectable in human urine only under steady-state conditions, and low-dose zopiclone was detectable only in overdose. The detection limit was less than 100 ng/mL (signal-to-noise ratio = 3) for the parent drugs.     

Comparison of Cozart microplate ELISA and GC-MS detection of methadone and metabolites in human hair

The purpose of this study was to determine the performance characteristics of the Cozart Methadone Microplate ELISA assay for the detection of methadone and methadone metabolites in hair specimens. One hundred and ten hair specimens were collected from volunteers (n=46) with a history of drug use and from drug-related deaths (n=64). The hair samples (approximately 20 mg) were extracted by sonication in methanol followed by overnight extraction in methanol at 60 degrees C. The methanol extract was evaporated to dryness, reconstituted in ELISA negative calibrator, and then analyzed. For gas chromatography-mass spectrometry (GC-MS) analysis, deuterated internal standard mixture [methadone-d9 and 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)-d3] and 0.1M HCI were added to approximately 20 mg of specimen or spiked blank hair and sonicated for 1 h. The pH was adjusted to neutral, and methadone and its primary metabolite, EDDP, were analyzed by GC-MS following solid-phase extraction using Bond Elute Certify columns and pH 7.4 phosphate buffer (0.1M). Forty hair specimens were confirmed positive for methadone by GC-MS. Concentrations ranged from 0.10 to 8.3 ng/mg for methadone and 0.1 to 1.2 ng/mg for EDDP. The true positives, true negatives, false positives, and false negatives for different cutoffs with the ELISA were determined by comparison of the ELISA response (normalized to weight of hair extracted) to the GC-MS results with a cutoff of 0.1 ng/mg for both methadone and EDDP as the reference method. The optimum cutoff for the Cozart Methadone Microplate ELISA was determined to be between 200 and 300 pg methadone equivalents/mg hair using a 20 mg hair sample. The Cozart Methadone Microplate EIA for methadone and metabolites in hair using a cut-off of 200 pg/mg hair with a 20 mg hair sample had a sensitivity of 95 +/- 2% and a specificity of 100 +/- 3.5% (vs GC-MS) and an accuracy of 98.2 +/- 1.3%.     

Serum and urine concentrations of flunitrazepam and metabolites, after a single oral dose, by immunoassay and GC-MS.

A clinical study was conducted to assess the ability of commercially available immunoassays to detect flunitrazepam (FNP) in plasma and urine samples and to compare the results with those obtained by gas chromatography-mass spectrometry (GC-MS). The clinical study consisted of four individuals (two male and two female) who had taken a single 2-mg dose of FNP. Serum was collected over a 48-h period and urine was collected over a 72-h period. The serum and urine samples were analyzed by the COBAS INTEGRA Serum Benzodiazepines assay (SBENZ), the TDx serum and urine Benzodiazepines assay, and GC-MS. The GC-MS procedure was developed for analysis of FNP and metabolites in plasma and urine using an acid hydrolysis step resulting in the formation of specific benzophenones corresponding to FNP and its metabolites. The relative sensitivities of the assays for the detection of FNP and metabolites in serum and urine were GC-MS > SBENZ > TDx. The immunoassay results for serum samples showed peak concentrations of FNP metabolites at 8 h after FNP ingestion for three individuals and at about 1 h for the fourth individual. The GC-MS, SBENZ, and TDx urine immunoassays detected drug above the stated limit of detection (LOD) in 44, 41, and 35 serial FNP urine samples, respectively. FNP metabolites were detected in urine samples with all three assays for up to 72 h after a 2-mg dose. The improved detection rate with the SBENZ assay as compared to the TDx assay is likely explained by its higher cross-reactivity with the major metabolite, 7-amino-flunitrazepam (7-amino-FNP), and its lower LOD.